SCHEMBL997050

SCHEMBL997050

CCCCCc1cc(O)c2c(c1)OC(C)(C)C1CCC(CO)=CC21

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 14/20 0.86
CNR1 P21554 13/20 0.86
ABHD12 Q8N2K0 3/20 0.78
ABHD6 Q9BV23 3/20 0.78
FAAH O00519 2/20 0.78
DRD3 P35462 2/20 0.78
TRPM8 Q7Z2W7 2/20 0.78
GPR55 Q9Y2T6 2/20 0.78
NR1I2 O75469 1/20 0.78
LDHA P00338 1/20 0.78
GLRA1 P23415 1/20 0.78
GPR183 P32249 1/20 0.78
ENPP2 Q13822 1/20 0.78
GPR18 Q14330 1/20 0.78
MEN1 O00255 1/20 0.72
KMT2A Q03164 1/20 0.72
TRPA1 O75762 1/20 0.66
HTR1A P08908 1/20 0.66
TRPV1 Q8NER1 1/20 0.66
TRPV3 Q8NET8 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23415525 1.00 CNR2 (0.86) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL21363770 1.00 CNR2 (0.86) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL31546115 1.00 CNR2 (0.86) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL20763968 1.00 CNR2 (0.86) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL31545117 0.93 CNR2 (0.78) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL22095410 0.93 CNR2 (1.00) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL20763972 0.93 CNR2 (1.00) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL31544994 0.93 CNR2 (1.00) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL21363560 0.93 CNR2 (1.00) CNR2CNR1ABHD12ABHD6FAAH
SCHEMBL31544941 0.93 CNR2 (1.00) CNR2CNR1ABHD12ABHD6FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083361-A1 NON-INVASIVE DETERMINATION OF A PHYSIOLOGICAL STATE OF INTEREST IN A SUBJECT ISBRG CORP (CA) 2026-03-26 US claimed
EP-4486336-A2 CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-01-08 EP claimed
CN-119136797-A CB1Ligand conjugated compounds and uses thereof 阿达尔克斯制药有限公司 2024-12-13 CN claimed
US-11918352-B2 Non-invasive determination of a physiological state of interest in a subject ISBRG CORP. (CA) 2024-03-05 US claimed
WO-2023168296-A2 CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-09-07 WO claimed
US-11686722-B2 Compositions and methods to detect molecules in a sample INFUSENSE CORP. (US) 2023-06-27 US claimed
US-20220211299-A1 NON-INVASIVE DETERMINATION OF A PHYSIOLOGICAL STATE OF INTEREST IN A SUBJECT ISBRG CORP. (CA) 2022-07-07 US claimed
US-20190331656-A1 COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE INFUSENSE CORP. 2019-10-31 US claimed
US-20260138132-A1 AMBIENT CONTAMINATION IN BREATH ANALYTE DETECTION AND MEASUREMENT HOUND LABS INC (US) 2026-05-21 US disclosed
US-12622920-B2 Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion PICO IP, LLC (US) 2026-05-12 US disclosed
US-20260083161-A1 CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS NATURAL EXTRACTION SYS LLC (US) 2026-03-26 US disclosed
US-20260083361-A1 NON-INVASIVE DETERMINATION OF A PHYSIOLOGICAL STATE OF INTEREST IN A SUBJECT ISBRG CORP (CA) 2026-03-26 US disclosed
US-20260076921-A1 Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis PIKE THERAPEUTICS INC (CA) 2026-03-19 US disclosed
US-12569504-B2 Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion Terry, Miles J. 2026-03-10 US disclosed
US-7465586-B2 Oral detection test for cannabinoid use LABONE, INC. (US) 2008-12-16 US disclosed
US-7465586-B2 Oral detection test for cannabinoid use LABONE, INC. (US) 2008-12-16 US disclosed
US-7465586-B2 Oral detection test for cannabinoid use LABONE, INC. (US) 2008-12-16 US disclosed
US-20080194041-A1 INTEGRATED DEVICE FOR ANALYTE, TESTING, CONFIRMATION, AND DONOR IDENTITY VERIFICATION LUDWIG & ROBINSON PLLC 2008-08-14 US disclosed
US-20060094123-A1 Oral detection test for cannabinoid use LABONE, INC. 2006-05-04 US disclosed
US-20040018151-A1 Use of anandamide/cannabinoid receptor/acceptor agonists in als screening and treatment methods ABOOD MARY E (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083361-A1 NON-INVASIVE DETERMINATION OF A PHYSIOLOGICAL STATE OF INTEREST IN A SUBJECT CNR1, CNR2, OGFR CNR2 2/4885CNR1 1/4885ABHD12 2278/4885
US-12569504-B2 Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion CNR1, CNR2, TMEM97 CNR2 2/4885CNR1 1/4885ABHD12 1961/4885
US-20260076921-A1 Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis SOST, CNR2, BHMT2 CNR2 2/4885CNR1 25/4885ABHD12 3388/4885
US-20260083161-A1 CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS CNR2, CNR1, OPRD1 CNR2 1/4885CNR1 2/4885ABHD12 750/4885
US-12622920-B2 Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion CNR1, CNR2, NPC1L1 CNR2 2/4885CNR1 1/4885ABHD12 2480/4885
US-20260138132-A1 AMBIENT CONTAMINATION IN BREATH ANALYTE DETECTION AND MEASUREMENT CNR2, CNR1, FAAH CNR2 1/4885CNR1 2/4885ABHD12 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.